Skip to Main Content

Paper Details

PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
Br J Cancer
12
2021
Author NameAffiliation
Alejandra BrunaPreclinical Modelling of Paediatric Cancer Evolution Team, Institute of Cancer Research
Carlos CaldasDepartment of Oncology and Cancer Research UK Cambridge Institute, University of Cambridge
Carlos CaldasNIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust
Rodrigo DienstmannVall d'Hebron Institute of Oncology
  • 1 - 4

Datasets